Welcome to our dedicated page for Wearable Devices Ltd. SEC filings (Ticker: WLDS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Wearable Devices Ltd. (WLDS) SEC filings page on Stock Titan aggregates the company’s public reports as a foreign private issuer, giving investors structured access to its regulatory disclosures. Wearable Devices files primarily on Form 6-K under the Securities Exchange Act of 1934, and these reports often attach press releases or transaction documents that explain key corporate and financing events.
Recent 6-K filings describe registered direct offerings of ordinary shares and pre-funded warrants, concurrent private placements of ordinary warrants, and an at-the-market sales agreement for ordinary shares. These filings outline terms such as offering structures, use of registration statements on Form F-3, warrant exercise conditions, lock-up provisions and commission arrangements with placement agents or sales agents. Other 6-Ks cover matters like annual and special general meetings, amendments to the company’s compensation policy, and increases in authorized share capital through changes to its articles of association.
For those analyzing WLDS, the filings also reference clinical and technology milestones when they are furnished as exhibits, such as the neurorehabilitation pilot with Soroka University Medical Center and grant support from the Israel Innovation Authority. While detailed financial statements are not included in the excerpts provided here, the 6-K framework allows the company to incorporate press releases and legal opinions by reference into existing registration statements on Form F-3 and Form S-8.
On Stock Titan, users can review these WLDS filings in chronological order and use AI-powered summaries to interpret complex legal and transactional language. The platform highlights essential elements of each report—such as the nature of an offering, key conditions, and referenced exhibits—so readers can more quickly understand how each filing relates to Wearable Devices’ capital structure, governance decisions and product-related disclosures.
Wearable Devices Ltd. (WLDS) entered a Securities Purchase Agreement for a registered direct offering to a single institutional investor, selling 655,000 ordinary shares at $2.67 per share and pre‑funded warrants for up to 575,000 shares at $2.6699 each, each with an accompanying ordinary warrant.
The Pre‑Funded Warrants are exercisable immediately at $0.0001 per share and include a 9.99% beneficial ownership cap. In a concurrent private placement, the Company will issue ordinary warrants for up to 1,230,000 shares with a $2.67 exercise price, exercisable upon shareholder approval and expiring five years after approval. The transaction uses an effective Form F‑3 and an October 29, 2025 prospectus supplement.
The Company agreed to 60‑day restrictions on additional issuances and variable‑rate transactions, subject to specified exceptions. Existing September 2025 investor warrants for 1,000,000 shares at $4.00 and 670,000 shares at $6.00 will have their exercise prices reduced to $2.67, subject to shareholder approval, and will expire five years after approval.
Wearable Devices (WLDS) amended its ATM program to $3,864,566 of ordinary shares under its Form F-3 with A.G.P., decreasing the prior $7,400,000 limit. Sales, if any, may be made as “at the market offerings” under Rule 415, with A.G.P. acting on a best efforts basis.
The company has sold $1,256,000 to date under the Sales Agreement. A.G.P. will receive a 3.0% commission on gross sales, and will be deemed an underwriter; indemnification applies as customary. WLDS shares trade on Nasdaq at $2.96 per share as of October 28, 2025. The aggregate market value of ordinary shares held by non‑affiliates was $54,829,754 as of October 29, 2025 under Form F‑3 I.B.5, and the company notes it has sold approximately $9,870,000 of securities in the past 12 months, leaving current I.B.5 capacity of $8,404,757.
Wearable Devices Ltd. (WLDS) filed a Form F-3 preliminary prospectus for the resale of up to 3,322,000 Ordinary Shares by the selling shareholder. These shares are issuable upon exercise of 3,322,000 immediately exercisable New Warrants that expire five years from issuance.
The company will not receive proceeds from any share resales. It may receive up to approximately $5.7 million in cash if the New Warrants are exercised in full for cash at an exercise price of $1.71 per share. As context, shares outstanding were 5,889,873 as of October 24, 2025, and would be 9,211,873 if all New Warrants are exercised for cash. The selling-holder table shows, including Armistice Capital 3,322,000.
The prospectus notes a beneficial ownership limitation of 4.99% (or 9.99% if elected) on certain warrants and highlights potential dilution risks from warrant exercises and future issuances.
Wearable Devices Ltd. (WLDS) reported results of its Annual and Special General Meeting. The meeting on October 24, 2025 was initially adjourned for lack of quorum at 11:00 a.m. (Israel time) but reconvened at 12:00 p.m., where a quorum was present. Shareholders approved Proposal Nos. 1 through 10 by the applicable required majority, as outlined in the September 19, 2025 proxy materials.
Key approvals: an amended and restated Compensation Policy covering new definitions, changes to advance notice and retirement terms, adjustments to grants, inclusion of a non‑compete period, revised special bonus terms, and updated acceleration events for unvested equity awards. Shareholders also approved an increase in authorized share capital by 450,000,000 ordinary shares, bringing total authorized ordinary shares to 500,000,000, and amended the Articles of Association accordingly, effective immediately after approval.
Wearable Devices Ltd. prospectus supplement discloses financing and capitalization details and highlights material risks. The company reported an explanatory paragraph in its interim financial statements expressing substantial doubt about its ability to continue as a going concern. The document lists multiple classes of potentially dilutive securities, including options, warrants, pre-funded warrants, RSUs and reserved shares, with explicit counts such as 3,322,000 Ordinary Shares subject to shareholder approval for warrants, 564,059 RSUs outstanding, 98,589 IPO warrants, and additional warrants exercisable at $4.00 and $6.00 for 1,000,000 and 670,000 shares respectively. A pro forma capitalization table shows total shareholders' equity increasing to $20,104 on a pro forma basis after recent issuances described, and the assumed offering price used for illustrative pro forma calculations is $5.37 per share. The supplement also outlines permitted offering and distribution methods, material terms for warrants and units, and estimated offering expenses including $15,000 legal fees and $3,000 accounting fees.
Wearable Devices Ltd. has entered into a Sales Agreement with A.G.P./Alliance Global Partners that allows it to sell, from time to time, up to $7,400,000 of its ordinary shares in an "at the market" offering. These shares will be issued under the company’s existing Form F-3 registration statement and related prospectus documents.
The company expects to use any proceeds from these share sales for working capital and general corporate purposes. It is not required to sell any shares, and the Sales Agent will act only on the company’s instructions while using commercially reasonable efforts to place the stock. A.G.P. will receive a commission equal to 3.0% of the aggregate gross proceeds from each sale, and the company will reimburse certain expenses and provide customary indemnification.
Wearable Devices Ltd., a foreign private issuer, submitted a Form 6-K to furnish the Notice of Meeting, Proxy Statement and Proxy Card for its Annual and Special General Meeting of Shareholders scheduled for October 24, 2025. Only shareholders of record holding ordinary shares at the close of business on September 26, 2024 are entitled to receive notice of, and vote at, the meeting in person or by proxy. The Form 6-K and its exhibit are also incorporated by reference into the company’s existing registration statements on Form S-8 and Form F-3.
Wearable Devices Ltd. filed a Form D for a new, non-public securities offering under Rule 506(b) seeking up to $4,020,000 in gross proceeds, with $0 sold to date and
Wearable Devices Ltd. filed a Form D to raise up to $4,000,000 under Regulation D, relying on Rule 506(b). The offering is for options/warrants and the securities issuable on exercise of those rights, with $0 sold to date and $4,000,000 remaining available. The company is incorporated in Israel and lists key executives including Asher Dahan (CEO & Chairman), CFO Tamar Fleisher, and other senior officers. The filing shows solicitation through A.G.P./Alliance Global Partners and reports $0 in sales commissions and finders fees and $0 of the offering proceeds proposed to be paid to named officers or directors. The minimum investment is listed as $0 and the issuer does not intend the offering to last more than one year.
Wearable Devices Ltd. (WLDS) prospectus supplement discloses capital structure changes, outstanding equity instruments, and a going-concern uncertainty. The company reports multiple classes of reserved and issuable Ordinary Shares (including options, warrants, RSUs and pre-funded warrants) totaling millions of potential shares that would dilute existing holders if issued. Pro forma adjustments reflect recent financings and a contemplated offering that raise net proceeds and increase pro forma net tangible book value per share from $1.67 to $1.91, and to $2.31 after this offering, with dilution per new investor estimated at $3.69 (61.48%). The filing lists specific reserved amounts (for example, 3,322,000 shares subject to shareholder approval and 564,059 RSUs) and describes distribution mechanics, underwriting limits, and legal/expense items.